Calypte Reports Second Quarter Results.BERKELEY Berkeley (bûr`klē), city (1990 pop. 102,724), Alameda co., W Calif., on the E shore of San Francisco Bay just N of Oakland; inc. 1878. Originally (1820) part of a Spanish rancho, the site was purchased by Americans in 1853. , Calif.--(BW HealthWire)--July 28, 1997--Calypte Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CALY) announced today its second quarter financial results, for the period ending June June: see month. 30, 1997. -0-
CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARY
(A Development Stage Enterprise)
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Period from
Feb. 18, 1988
Three Six (inception)
Months Ended Months Ended through
June 30, June 30, June 30,
1997 1996 1997 1996 1997
Revenues:
Product sales $ 117 $ -- $ 132 $ -- $ 262
Earned under research
and development
contracts,
substantially from
related parties -- -- -- -- 2,390
Total revenue 117 -- 132 -- 2,652
Operating expenses:
Product costs 684 -- 1,218 -- 2,303
Research and
development costs 984 1,743 2,142 3,571 28,240
Purchased in-process
research and
development costs -- -- -- -- 2,500
Selling, general
and administrative
costs 593 820 1,186 1,716 15,446
Total expenses 2,261 2,563 4,546 5,287 48,489
Loss from operations (2,144) (2,563) (4,414) (5,287) (45,837)
Interest income,
interest expense and
other income 21 (63) 52 (155) 31
Loss before income taxes
and extraordinary
item (2,123) (2,626) (4,362) (5,442) (45,806)
Income taxes (2) (2) (2) (2) (65)
Loss before
extraordinary item (2,125) (2,628) (4,364) (5,444) (45,871)
Extraordinary gain on
debt extinguishment -- -- -- -- 485
Net loss (2,125) (2,628) (4,364) (5,444) (45,386)
Less dividend on
mandatorily redeemable
Series A preferred
stock (30) (30) (60) (60) (916)
Net loss attributable
to common
stockholders $(2,155) $(2,658) $(4,424) $(5,504) $(46,302)
Net loss per share
attributable to
common stockholders $ (0.21) $ (0.35) $ (0.42) $ (0.75) --
Weighted average shares
used to compute net loss
per share attributable
to common
stockholders 10,477 7,665 10,471 7,300 --
CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARY
(A Development Stage Enterprise)
CONSOLIDATED CONDENSED BALANCE SHEET DATA
(in thousands, except share data)
June 30, 1997 Dec. 31, 1996
(Unaudited)
Cash and cash equivalents $ 4,076 $ 7,924
Working capital 1,871 6,067
Total assets 6,469 10,347
Long-term portion of capital lease
obligations and notes payable 501 764
Mandatorily redeemable Series A
preferred stock 1,916 1,856
Total stockholders' equity (deficit) 1,110 5,416
-0- Calypte Calypte is a genus of hummingbirds. It consists of two small species. They are:
"National Geographic" Biomedical Corp. is a Berkeley, California-based health care company dedicated to the development and commercialization of urine-based diagnostic products and services for HIV-1, sexually transmitted diseases Sexually transmitted diseases Infections that are acquired and transmitted by sexual contact. Although virtually any infection may be transmitted during intimate contact, the term sexually transmitted disease is restricted to conditions that are largely and other chronic illnesses. Calypte stock is listed on the Nasdaq SmallCap market under the symbol "CALY." CONTACT: Calypte Biomedical Corporation, Berkeley Jack Davis Jack Davis may refer to:
John DiPietro, 510/814-8500 (CFO See Chief Financial Officer. ) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion